Top

Cancer Cell International

Published in:

01-12-2021 | Xanthine Alkaloid | Primary research

Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma

Authors: Zhen Lin, Yi-Zhao Xie, Ming-Chun Zhao, Pin-Pin Hou, Juan Tang, Guang-Liang Chen

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Xanthine dehydrogenase (XDH) is a critical enzyme involved in the oxidative metabolism of purines, pterin and aldehydes and a central component of the innate immune system. However, the prognostic value of XDH in predicting tumor-infiltrating lymphocyte abundance, the immune response, and survival in different cancers, including hepatocellular carcinoma (HCC), is still unclear.

Methods

XDH expression was analyzed in multiple databases, including Oncomine, the Tumor Immune Estimation Resource (TIMER), the Kaplan–Meier plotter database, the Gene Expression Profiling Interactive Analysis (GEPIA) database, and The Cancer Genome Atlas (TCGA). XDH-associated transcriptional profiles were detected with an mRNA array, and the levels of infiltrating immune cells were validated by immunohistochemistry (IHC) of HCC tissues. A predictive signature containing multiple XDH-associated immune genes was established using the Cox regression model.

Results

Decreased XDH mRNA expression was detected in human cancers originating from the liver, bladder, breast, colon, bile duct, kidney, and hematolymphoid system. The prognostic potential of XDH mRNA expression was also significant in certain other cancers, including HCC, breast cancer, kidney or bladder carcinoma, gastric cancer, mesothelioma, lung cancer, and ovarian cancer. In HCC, a low XDH mRNA level predicted poorer overall survival, disease-specific survival, disease-free survival, and progression-free survival. The prognostic value of XDH was independent of the clinical features of HCC patients. Indeed, XDH expression in HCC activated several immune-related pathways, including the T cell receptor, PI3K-AKT, and MAPK signaling pathways, which induced a cytotoxic immune response. Importantly, the microenvironment of XDH^high HCC tumors contained abundant infiltrating CD8 + T cells but not exhausted T cells. A risk prediction signature based on multiple XDH-associated immune genes was revealed as an independent predictor in the TCGA liver cancer cohort.

Conclusion

These findings suggest that XDH is a valuable prognostic biomarker in HCC and other cancers and indicate that it may function in tumor immunology. Loss of XDH expression may be an immune evasion mechanism for HCC.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252(6):903–12. https://doi.org/10.1097/SLA.0b013e3181efc656.CrossRefPubMed

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. https://doi.org/10.1053/j.gastro.2007.04.061.CrossRefPubMed

Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–80. https://doi.org/10.1016/S1470-2045(20)30011-5.CrossRefPubMed

Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122(11):1757–65. https://doi.org/10.1002/cncr.29971.CrossRefPubMed

Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol. 2020;72(1):167–82. https://doi.org/10.1016/j.jhep.2019.08.014.CrossRefPubMed

Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18(2):291–7. https://doi.org/10.1016/j.aohep.2019.04.003.CrossRefPubMed

Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020;39(18):3620–37. https://doi.org/10.1038/s41388-020-1249-9.CrossRefPubMedPubMedCentral

10.

Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 2019;25(24):2977–89. https://doi.org/10.3748/wjg.v25.i24.2977.CrossRefPubMedPubMedCentral

11.

Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7(1):267. https://doi.org/10.1186/s40425-019-0749-z.CrossRefPubMedPubMedCentral

12.

Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta. 2014;1842(9):1502–17. https://doi.org/10.1016/j.bbadis.2014.05.022.CrossRefPubMed

13.

Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine oxidoreductase in cancer: more than a differentiation marker. Cancer Med. 2016;5(3):546–57. https://doi.org/10.1002/cam4.601.CrossRefPubMed

14.

Ohtsubo T, Rovira II, Starost MF, Liu C, Finkel T. Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circ Res. 2004;95(11):1118–24. https://doi.org/10.1161/01.RES.0000149571.96304.36.CrossRefPubMed

15.

Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, et al. Xanthine oxidoreductase regulates macrophage IL1beta secretion upon NLRP3 inflammasome activation. Nat Commun. 2015;6:6555. https://doi.org/10.1038/ncomms7555.CrossRefPubMed

16.

Xu P, Huecksteadt TP, Harrison R, Hoidal JR. Molecular cloning, tissue expression of human xanthine dehydrogenase. Biochem Biophys Res Commun. 1994;199(2):998–1004. https://doi.org/10.1006/bbrc.1994.1328.CrossRefPubMed

17.

Wright RM, Vaitaitis GM, Wilson CM, Repine TB, Terada LS, Repine JE. cDNA cloning, characterization, and tissue-specific expression of human xanthine dehydrogenase/xanthine oxidase. Proc Natl Acad Sci USA. 1993;90(22):10690–4. https://doi.org/10.1073/pnas.90.22.10690.CrossRefPubMedPubMedCentral

18.

Sato A, Nishino T, Noda K, Amaya Y, Nishino T. The structure of chicken liver xanthine dehydrogenase. cDNA cloning and the domain structure. J Biol Chem. 1995;270(6):2818–26. https://doi.org/10.1074/jbc.270.6.2818.CrossRefPubMed

19.

Harmon DB, Mandler WK, Sipula IJ, Dedousis N, Lewis SE, Eckels JT, et al. Hepatocyte-specific ablation or whole-body inhibition of xanthine oxidoreductase in mice corrects obesity-induced systemic hyperuricemia without improving metabolic abnormalities. Diabetes. 2019;68(6):1221–9. https://doi.org/10.2337/db18-1198.CrossRefPubMedPubMedCentral

20.

Srivastava M, Kale RK. Radiomodfication of xanthine oxidoreductase system in the liver of mice by phenylmethylsulfonyl fluoride and dithiothreitol. Radiat Res. 2000;154(1):94–103. https://doi.org/10.1667/0033-7587(2000)154[0094:roxosi]2.0.co;2.CrossRefPubMed

21.

Chen GL, Ye T, Chen HL, Zhao ZY, Tang WQ, Wang LS, et al. Xanthine dehydrogenase downregulation promotes TGFbeta signaling and cancer stem cell-related gene expression in hepatocellular carcinoma. Oncogenesis. 2017;6(9): e382. https://doi.org/10.1038/oncsis.2017.81.CrossRefPubMedPubMedCentral

22.

Sun Q, Zhang Z, Lu Y, Liu Q, Xu X, Xu J, et al. Loss of xanthine oxidoreductase potentiates propagation of hepatocellular carcinoma stem cells. Hepatology. 2020;71(6):2033–49. https://doi.org/10.1002/hep.30978.CrossRefPubMed

23.

Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res. 2005;11(12):4372–81. https://doi.org/10.1158/1078-0432.CCR-04-2280.CrossRefPubMed

24.

Linder N, Haglund C, Lundin M, Nordling S, Ristimaki A, Kokkola A, et al. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol. 2006;59(9):965–71. https://doi.org/10.1136/jcp.2005.032524.CrossRefPubMedPubMedCentral

25.

Linder N, Butzow R, Lassus H, Lundin M, Lundin J. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma. Gynecol Oncol. 2012;124(2):311–8. https://doi.org/10.1016/j.ygyno.2011.10.026.CrossRefPubMed

26.

Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, et al. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011;71(2):186–90. https://doi.org/10.1016/j.lungcan.2010.05.006.CrossRefPubMed

27.

Linder N, Martelin E, Lundin M, Louhimo J, Nordling S, Haglund C, et al. Xanthine oxidoreductase—clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells. Eur J Cancer. 2009;45(4):648–55. https://doi.org/10.1016/j.ejca.2008.10.036.CrossRefPubMed

28.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–80. https://doi.org/10.1593/neo.07112.CrossRefPubMedPubMedCentral

29.

Nagy A, Munkacsy G, Gyorffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11(1):6047. https://doi.org/10.1038/s41598-021-84787-5.CrossRefPubMedPubMedCentral

30.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10. https://doi.org/10.1158/0008-5472.CAN-17-0307.CrossRefPubMedPubMedCentral

31.

Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. https://doi.org/10.1186/s13059-016-1028-7.CrossRefPubMedPubMedCentral

32.

Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971. https://doi.org/10.1038/ncomms9971.CrossRefPubMed

33.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-102. https://doi.org/10.1093/nar/gkx247.CrossRefPubMedPubMedCentral

34.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47. https://doi.org/10.1093/nar/gkv007.CrossRefPubMedPubMedCentral

35.

Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7. https://doi.org/10.1089/omi.2011.0118.CrossRefPubMedPubMedCentral

36.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

37.

Chen GL, Li R, Chen XX, Wang J, Cao S, Song R, et al. Fra-2/AP-1 regulates melanoma cell metastasis by downregulating Fam212b. Cell Death Differ. 2021;28(4):1364–78. https://doi.org/10.1038/s41418-020-00660-4.CrossRefPubMed

38.

Chen GL, Luo Y, Eriksson D, Meng X, Qian C, Bauerle T, et al. High fat diet increases melanoma cell growth in the bone marrow by inducing osteopontin and interleukin 6. Oncotarget. 2016;7(18):26653–69. https://doi.org/10.18632/oncotarget.8474.CrossRefPubMedPubMedCentral

39.

Wei L, Delin Z, Kefei Y, Hong W, Jiwei H, Yange Z. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. Oncoimmunology. 2020;9(1):1672495. https://doi.org/10.1080/2162402X.2019.1672495.CrossRefPubMed

40.

Choi I, Wells BJ, Yu C, Kattan MW. An empirical approach to model selection through validation for censored survival data. J Biomed Inform. 2011;44(4):595–606. https://doi.org/10.1016/j.jbi.2011.02.005.CrossRefPubMed

41.

Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE. 2013;8(9): e74250. https://doi.org/10.1371/journal.pone.0074250.CrossRefPubMedPubMedCentral

42.

Saha-Chaudhuri P, Heagerty PJ. Non-parametric estimation of a time-dependent predictive accuracy curve. Biostatistics. 2013;14(1):42–59. https://doi.org/10.1093/biostatistics/kxs021.CrossRefPubMed

43.

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70. https://doi.org/10.1200/JCO.2007.12.9791.CrossRefPubMed

44.

Stirpe F, Ravaioli M, Battelli MG, Musiani S, Grazi GL. Xanthine oxidoreductase activity in human liver disease. Am J Gastroenterol. 2002;97(8):2079–85. https://doi.org/10.1111/j.1572-0241.2002.05925.x.CrossRefPubMed

45.

Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2): e213. https://doi.org/10.1136/esmoopen-2017-000213.CrossRef

46.

Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T, et al. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis. Sci Rep. 2017;7(1):7525. https://doi.org/10.1038/s41598-017-08128-1.CrossRefPubMedPubMedCentral

47.

Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, et al. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med. 2019;17(1):106. https://doi.org/10.1186/s12916-019-1341-6.CrossRefPubMedPubMedCentral

48.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. https://doi.org/10.1007/s10120-016-0622-4.CrossRef

49.

Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678–83. https://doi.org/10.1200/JCO.2011.37.8539.CrossRefPubMed

50.

Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6: e1792. https://doi.org/10.1038/cddis.2015.162.CrossRefPubMedPubMedCentral

51.

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021. https://doi.org/10.1038/s41575-021-00438-0.CrossRefPubMedPubMedCentral

52.

Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. https://doi.org/10.1038/s41571-018-0073-4.CrossRefPubMed

53.

Nakano S, Eso Y, Okada H, Takai A, Takahashi K, Seno H. Recent advances in immunotherapy for hepatocellular carcinoma. Cancers. 2020. https://doi.org/10.3390/cancers12040775.CrossRefPubMedPubMedCentral

54.

Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2021;70(1):204–14. https://doi.org/10.1136/gutjnl-2020-321702.CrossRefPubMed

55.

Saidak Z, Louandre C, Dahmani S, Sauzay C, Guedda S, Chauffert B, et al. A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates. Biosci Rep. 2018. https://doi.org/10.1042/BSR20171716.

56.

Peng Y, Liu C, Li M, Li W, Zhang M, Jiang X, et al. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell Int. 2021;21(1):98. https://doi.org/10.1186/s12935-021-01792-4.CrossRefPubMedPubMedCentral

57.

Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F, et al. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med. 2020;18(1):67. https://doi.org/10.1186/s12967-020-02255-6.CrossRefPubMedPubMedCentral

58.

Xie P, Ma Y, Yu S, An R, He J, Zhang H. Development of an immune-related prognostic signature in breast cancer. Front Genet. 2019;10:1390. https://doi.org/10.3389/fgene.2019.01390.CrossRefPubMed

59.

Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, et al. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010;28(7):765–73. https://doi.org/10.3109/07357900903095755.CrossRefPubMedPubMedCentral

60.

Zhou C, Li C, Yan F, Zheng Y. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma. Cancer Cell Int. 2020;20(1):541. https://doi.org/10.1186/s12935-020-01560-w.CrossRefPubMedPubMedCentral

61.

Song Q, Shang J, Yang Z, Zhang L, Zhang C, Chen J, et al. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med. 2019;17(1):70. https://doi.org/10.1186/s12967-019-1824-4.CrossRefPubMedPubMedCentral

62.

Zhao K, Xu L, Li F, Ao J, Jiang G, Shi R, et al. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature. 2020. Biosci Rep.

63.

Qiao GJ, Chen L, Wu JC, Li ZR. Identification of an eight-gene signature for survival prediction for patients with hepatocellular carcinoma based on integrated bioinformatics analysis. PeerJ. 2019;7: e6548. https://doi.org/10.7717/peerj.6548.CrossRefPubMedPubMedCentral

64.

Liu GM, Zeng HD, Zhang CY, Xu JW. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int. 2019;19:138. https://doi.org/10.1186/s12935-019-0858-2.CrossRefPubMedPubMedCentral

65.

Wang Z, Teng D, Li Y, Hu Z, Liu L, Zheng H. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction. Life Sci. 2018;203:83–91. https://doi.org/10.1016/j.lfs.2018.04.025.CrossRefPubMed

66.

Zheng Y, Liu Y, Zhao S, Zheng Z, Shen C, An L, et al. Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. Cancer Manag Res. 2018;10:6079–96. https://doi.org/10.2147/CMAR.S181396.CrossRefPubMedPubMedCentral

67.

Chen W, Ou M, Tang D, Dai Y, Du W. Identification and validation of immune-related gene prognostic signature for hepatocellular carcinoma. J Immunol Res. 2020;2020:5494858. https://doi.org/10.1155/2020/5494858.CrossRefPubMedPubMedCentral

68.

Xu D, Wang Y, Zhou K, Wu J, Zhang Z, Zhang J, et al. Development and validation of a novel 8 immune gene prognostic signature based on the immune expression profile for hepatocellular carcinoma. Onco Targets Ther. 2020;13:8125–40. https://doi.org/10.2147/OTT.S263047.CrossRefPubMedPubMedCentral

Title: Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma
Authors: Zhen Lin
Yi-Zhao Xie
Ming-Chun Zhao
Pin-Pin Hou
Juan Tang
Guang-Liang Chen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Xanthine Alkaloid
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Biomarkers
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02173-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Using dynamic cell communication improves treatment strategies of breast cancer

Identification of an immune-related signature indicating the dedifferentiation of thyroid cells

Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion

Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Recombinant immunotoxins development for HER2-based targeted cancer therapies

To explore immune synergistic function of Quercetin in inhibiting breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer